Aptevo Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by Aptevo Therapeutics Inc. on June 7, 2022. The filing details the voting outcomes for five proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders approved all five proposals presented at the Annual Meeting:
- Proposal 1 (Election of Directors): Marvin L. White and John E. Niederhuber, M.D. were elected to the Board of Directors. Both nominees received significant "FOR" votes (1,407,493 and 1,327,090 respectively) against "WITHHELD" votes of 211,775 and 292,178.
- Proposal 2 (Auditor Ratification): The appointment of Moss Adams LLP as the independent registered public accounting firm for 2022 was approved with 3,139,114 "FOR" votes.
- Proposal 3 (Stock Incentive Plan): The 2018 Stock Incentive Plan (as Amended and Restated) was approved with 1,519,205 "FOR" votes.
- Proposal 4 (Say-on-Pay): The non-binding advisory vote on executive compensation was approved with 1,477,018 "FOR" votes.
- Proposal 5 (Say-on-Pay Frequency): Stockholders approved a one-year interval for future advisory votes on executive compensation, with 1,317,290 votes for the one-year option.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the quorum status to contextualize the voting percentages.
- Review the definitive proxy statement filed on April 27, 2022, for detailed descriptions of the director nominees and the amended stock incentive plan.
- Confirm the specific terms of the Moss Adams LLP engagement for the 2022 fiscal year.
- Monitor future filings for the company's financial performance, as this 8-K contains no financial data.